Neutrophil CD64 Expression as A Biomarker in the Early Diagnosis of Sepsis in Malignant Hematologic Disease--Review.
10.7534/j.issn.1009-2137.2016.01.046
- Author:
Yu-Xi SHANG
1
;
Li-Ru WANG
2
Author Information
1. Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
2. Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China. E-mail: wanglirumail@126.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers;
metabolism;
Early Diagnosis;
Hematologic Diseases;
complications;
Humans;
Neutrophils;
metabolism;
Prognosis;
Receptors, IgG;
metabolism;
Sepsis;
complications;
diagnosis
- From:
Journal of Experimental Hematology
2016;24(1):241-244
- CountryChina
- Language:Chinese
-
Abstract:
Malignant hematologic disease with sepsis has been characterized by high mortality and difficulty in diagnosis at early stage. A good biomarker may help to improve the accuracy of diagnosis and to reduce the mortality rate. In the early diagnosis of sepsis, neutrophil CD64 expression is a better candidate for biomarker rather than C-reactive proteins. Moreover, neutrophil CD64 expression is also helpful for assessing the severity of infection and prognosis of disease. Unfortunately, there are few studies of neutrophil CD64 expression on the early diagnosis of malignant hematologic diseases. This review focuses on the advantages, limitations, feasibilities and progresses of neutrophil CD64 expression in the early diagnosis of infection in malignant hematologic diseases in this paper.
